Physician profile
Kathleen E Lambert
NPI 1689651390
$52,422.01
in general payments reported to CMS, 2019-2025
46 companies · $5,159 in 2025
The $5,159 reported for 2025 was more than what 82% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10K · 2020: $8,827 · 2021: $500 · 2022: $2,891 · 2023: $17K · 2024: $7,876 · 2025: $5,159.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $23K · Food and Beverage: $3,413 · Consulting Fee: $3,285 · Travel and Lodging: $193.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $23,237.50 |
| Food and Beverage | $3,412.62 |
| Consulting Fee | $3,285.00 |
| Travel and Lodging | $192.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $48,022.79 | 2019-2025 | Tecvayli, Darzalex, Carvykti |
| Amgen INC. | $1,650.00 | 2019 | |
| Novartis Pharmaceuticals Corporation | $275.54 | 2023-2025 | |
| Abbvie INC. | $181.50 | 2024-2025 | |
| Daiichi Sankyo INC. | $179.31 | 2024-2025 | Enhertu, Vanflyta, Injectafer |
| Merck Sharp & Dohme LLC | $153.86 | 2024-2025 | Keytruda, Lynparza |
| Astrazeneca Pharmaceuticals LP | $151.47 | 2024-2025 | Enhertu, Lynparza, Tagrisso |
| Celgene Corporation | $105.79 | 2024-2025 | Reblozyl, Opdualag |
| Beone Medicines USA, INC. | $104.92 | 2025 | Tevimbra, Brukinsa |
| Springworks Therapeutics, INC. | $103.68 | 2025 | |
| Gilead Sciences, INC. | $101.10 | 2024-2025 | Trodelvy |
| Genentech USA, INC. | $100.94 | 2024-2025 | Itovebi, Phesgo, Kadcyla |
| Takeda Pharmaceuticals U.S.A., INC. | $97.71 | 2024-2025 | Fruzaqla, Alunbrig, Ninlaro |
| Jazz Pharmaceuticals INC. | $85.25 | 2024 | |
| Exelixis INC. | $82.48 | 2019-2022 |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $73.85 | 2024-2025 | |
| Astellas Pharma US INC | $69.98 | 2024-2025 | Vyloy, Padcev |
| Invivyd INC | $59.73 | 2025 | Pemgarda |
| Tersera Therapeutics LLC | $55.26 | 2025 | Zoladex, Xermelo |
| Tempus Ai, INC | $51.02 | 2024-2025 | Xt Cdx |
| Array Biopharma INC | $51.00 | 2024-2025 | Braftovi, Mektovi, Tukysa |
| Incyte Corporation | $42.34 | 2024-2025 | Jakafi, Niktimvo |
| Stemline Therapeutics INC. | $41.70 | 2024-2025 | Orserdu |
| Pharmaessentia USA Corporation | $41.59 | 2024-2025 | Besremi |
| Glaxosmithkline, LLC. | $40.47 | 2025 | Blenrep, Jemperli, Zejula |
| Bayer Healthcare Pharmaceuticals INC. | $39.04 | 2023-2024 | |
| Sumitomo Pharma America, INC. | $34.63 | 2024-2025 | Orgovyx |
| Aveo Pharmaceuticals, INC. | $32.90 | 2024 | |
| Nuvation Bio INC. | $32.14 | 2025 | Ibtrozi |
| Adc Therapeutics America, INC. | $27.68 | 2025 | |
| Sobi, INC | $26.83 | 2025 | |
| Alexion Pharmaceuticals, INC. | $25.69 | 2024 | Ultomiris |
| Pharmacyclics LLC, An Abbvie Company | $25.36 | 2023 | Epkinly, Imbruvica |
| Beigene USA, INC. | $25.34 | 2024 | Brukinsa |
| Servier Pharmaceuticals LLC | $25.00 | 2025 | |
| Immunogen, INC. | $22.84 | 2024 | Elahere |
| Caris Mpi, INC. | $22.52 | 2025 | Mi Cancer Seek |
| Geron Corporation | $22.07 | 2025 | Rytelo |
| Eisai INC. | $21.73 | 2025 | |
| Rigel Pharmaceuticals, INC. | $19.89 | 2024 | Rezlidhia, Tavalisse |
| Legend Biotech USA INC. | $19.37 | 2024 | |
| Deciphera Pharmaceuticals INC. | $17.82 | 2024 | Qinlock |
| Agios Pharmaceuticals, INC. | $16.88 | 2025 | Pyrukynd |
| Genzyme Corporation | $16.28 | 2025 | |
| Corcept Therapeutics | $16.19 | 2025 | Korlym |
| Janssen Scientific Affairs, LLC | $8.53 | 2023 | Darzalex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathleen Lambert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.